Study of Gemcitabine and Vindesine in Lung Cancer
Author Information
Author(s): Sørensen J B, Bergman B, Nielsen A L, Krarup M, Dombernowsky P, Hansen H H
Primary Institution: Department of Oncology, Finsen Center, National University Hospital, Copenhagen, Denmark
Hypothesis
The combination of gemcitabine and vindesine will be effective in treating patients with non-resectable non-small-cell lung cancer.
Conclusion
The combination of gemcitabine and vindesine does not appear to be promising for further examination due to toxicity and disappointing activity.
Supporting Evidence
- One complete and seven partial responses were observed among 40 assessable patients.
- Median response duration was 31 weeks.
- Median survival time was also 31 weeks.
Takeaway
Doctors tested two medicines to help people with a type of lung cancer, but they found that the medicines didn't work well together and caused some side effects.
Methodology
Patients received gemcitabine and vindesine in a specific schedule over several weeks.
Limitations
The study had a small sample size and reported significant toxicity.
Participant Demographics
Median age was 56 years; 57% were men, with various types of lung cancer.
Statistical Information
Confidence Interval
95% confidence limits 9–36%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website